Ironwood Pharmaceuticals Inc Class A IRWD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IRWD is a good fit for your portfolio.
News
-
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
-
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
-
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
-
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
-
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
-
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
-
The Russell 2000 Index has soared, but you -2-
-
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
Trading Information
- Previous Close Price
- $8.10
- Day Range
- $7.95–8.14
- 52-Week Range
- $7.53–15.70
- Bid/Ask
- $7.50 / $8.38
- Market Cap
- $1.26 Bil
- Volume/Avg
- 17 / 4.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- 7.16
- Price/Sales
- 2.84
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 267
- Website
- https://www.ironwoodpharma.com
Comparables
Valuation
|
Metric
|
IRWD
|
INVA
|
AMLX
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.16 | 9.13 | 1.51 |
Price/Book Value | — | 1.41 | 0.28 |
Price/Sales | 2.84 | 4.19 | 0.33 |
Price/Cash Flow | 7.29 | 7.85 | 1.61 |
Price/Earnings
IRWD
INVA
AMLX
Financial Strength
|
Metric
|
IRWD
|
INVA
|
AMLX
|
|---|---|---|---|
Quick Ratio | 0.80 | 7.28 | 5.01 |
Current Ratio | 0.84 | 9.03 | 5.66 |
Interest Coverage | −43.71 | 10.31 | — |
Quick Ratio
IRWD
INVA
AMLX
Profitability
|
Metric
|
IRWD
|
INVA
|
AMLX
|
|---|---|---|---|
Return on Assets (Normalized) | −126.33% | 14.79% | 18.55% |
Return on Equity (Normalized) | −1,415.33% | 29.29% | 21.48% |
Return on Invested Capital (Normalized) | −141.06% | 16.71% | 17.45% |
Return on Assets
IRWD
INVA
AMLX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Tftzxjvzx | Hbcpfc | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Xsvqjtby | Cfl | $68.9 Bil | |
HLN
| Haleon PLC ADR | Pkxshgl | Yzbm | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Svgqwzd | Ppnkz | $14.8 Bil | |
VTRS
| Viatris Inc | Hshqqycxb | Tlqk | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Wdqkqdzrm | Shvn | $11.9 Bil | |
CTLT
| Catalent Inc | Zlvbkbxn | Ysfvdc | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Fhhknlt | Ykfhz | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Nrhqwfdc | Cvvh | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xywflzjwm | Knbhfs | $3.5 Bil |